ALX Oncology (ALXO) said Friday that two phase 2 trials evaluating evorpacept in combination with Merck's (MRK) Keytruda in patients with advanced head and neck squamous cell carcinoma failed to meet their primary endpoints of improved objective response rates.
The company said efficacy data from the trials do not support advancing the combination into a registrational study and it will no longer pursue the combination therapy in advanced head and neck squamous cell carcinoma.
ALX said, however, that several trials of evorpacept in combination with other anti-cancer antibodies will continue based on established proof-of-concept.
ALX Oncology shares were down more than 4% in recent Friday trading.
Price: 0.58, Change: -0.02, Percent Change: -3.49
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.